Literature DB >> 10963445

Population-based genetic study of childhood hearing impairment in the Trent Region of the United Kingdom.

M J Parker1, H M Fortnum, I D Young, A C Davis, R F Mueller.   

Abstract

The objective of the study was to investigate childhood hearing impairment in a population-based sample from a genetic perspective. Participants included 82 families with hearing-impaired children (aged 4-13) previously ascertained in the Trent Health Region. A questionnaire was mailed to all families, followed by a home visit and Connexin-26 35delG mutation screen. The Connexin-26 35delG mutation was identified in seven families (approximately 10 per cent of non-syndromal hearing impairment). Children of these families were significantly more likely than children with other modes of inheritance to have a profound hearing loss with a flat audiogram profile. The families of children with a significant admission to a neonatal intensive care unit were significantly less likely to have had genetic counselling. Eight families visited were found to have features suggestive of a genetic syndrome that had not been previously assigned a specific diagnosis. The study concluded that hearing-impaired children should be investigated systematically according to an agreed-upon protocol, which should include Connexin-26 35delG mutation analysis at least for those with severe-to-profound hearing loss.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10963445     DOI: 10.3109/00206090009073083

Source DB:  PubMed          Journal:  Audiology        ISSN: 0020-6091


  2 in total

1.  Cognition in children with sensorineural hearing loss: etiologic considerations.

Authors:  Suzanne K Pierson; Susan E Caudle; Kevin R Krull; Jody Haymond; Ross Tonini; John S Oghalai
Journal:  Laryngoscope       Date:  2007-09       Impact factor: 3.325

Review 2.  An overview of motor skill performance and balance in hearing impaired children.

Authors:  Venkadesan Rajendran; Finita Glory Roy
Journal:  Ital J Pediatr       Date:  2011-07-14       Impact factor: 2.638

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.